S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
15 A.I. Trading Opportunities a Day (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
15 A.I. Trading Opportunities a Day (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
15 A.I. Trading Opportunities a Day (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
15 A.I. Trading Opportunities a Day (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
15 A.I. Trading Opportunities a Day (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
15 A.I. Trading Opportunities a Day (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
15 A.I. Trading Opportunities a Day (Ad)
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Biden, GOP reach debt-ceiling deal, now Congress must approve it to prevent calamitous default
15 A.I. Trading Opportunities a Day (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Earnings Date, Estimates & Call Transcripts

$8.75
+0.20 (+2.34%)
(As of 05/26/2023 ET)
Compare
Today's Range
$8.53
▼
$8.84
50-Day Range
$8.47
▼
$10.83
52-Week Range
$1.81
▼
$11.22
Volume
558,308 shs
Average Volume
1.36 million shs
Market Capitalization
$853.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.57
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
Aug. 10Estimated
Actual EPS
(Mar. 16)
-$0.30
Consensus EPS
(Mar. 16)
-$0.30
Last Year's Q1 EPS
(3/17/2022)
-$0.34
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

CBAY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CBAY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CymaBay Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20233($0.32)$0.06($0.18)
Q2 20234($0.32)$0.04($0.22)
Q3 20234($0.33)($0.28)($0.31)
Q4 20234($0.45)$0.00($0.25)
FY 202315($1.42)($0.18)($0.95)
Q1 20241($0.34)($0.34)($0.34)
Q2 20241($0.41)($0.41)($0.41)
Q3 20241($0.47)($0.47)($0.47)
Q4 20241($0.49)($0.49)($0.49)
FY 20244($1.71)($1.71)($1.71)

CBAY Earnings Date and Information

CymaBay Therapeutics last issued its earnings data on March 16th, 2023. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.30). CymaBay Therapeutics has generated ($1.18) earnings per share over the last year (($1.18) diluted earnings per share). Earnings for CymaBay Therapeutics are expected to remain at ($1.01) per share in the coming year. CymaBay Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 10th, 2023 based off prior year's report dates.

CymaBay Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/10/2023
(Estimated)		        
3/16/2023Q4 2022($0.30)($0.30)($0.30)    
11/14/2022Q3 2022($0.30)($0.28)+$0.02($0.28)
8/11/2022Q2 2022($0.30)($0.31)($0.01)($0.31)    
5/12/2022Q1 2022($0.31)($0.32)($0.01)($0.32)    
3/17/2022Q4 2021($0.36)($0.34)+$0.02($0.34)    
11/10/20219/30/2021($0.26)($0.33)($0.07)($0.33)  
8/12/20216/30/2021($0.27)($0.34)($0.07)($0.34)    
5/13/20213/31/2021($0.24)($0.25)($0.01)($0.25)  
3/24/202112/31/2020($0.20)($0.23)($0.03)($0.23)  
11/5/20209/30/2020($0.17)($0.17)($0.17)  
8/10/20206/30/2020($0.23)($0.16)+$0.07($0.16)  
5/11/20203/31/2020($0.31)($0.19)+$0.12($0.19)  
3/12/2020Q4 2019($0.39)($0.43)($0.04)($0.28)  
11/5/2019Q3($0.37)($0.38)($0.01)($0.38)  
8/7/2019Q2 2019($0.37)($0.35)+$0.02($0.35)
5/8/20193/31/2019($0.34)($0.37)($0.03)($0.37)  
2/28/2019Q4 2018($0.36)($0.32)+$0.04($0.32)
11/6/20189/30/2018($0.30)($0.34)($0.04)($0.34)
8/10/2018Q2 2018($0.25)($0.2910)($0.0410)($0.30)
5/9/2018Q1 2018($0.14)($0.32)($0.18)($0.32)$5.00 million
3/15/2018Q4 2017($0.17)($0.11)+$0.06($0.11)$1.25 million$5.20 million  
11/8/2017Q3 2017($0.19)($0.21)($0.02)($0.21)$9.50 million
8/10/2017Q2 2017($0.25)($0.31)($0.06)($0.31)
5/11/2017Q1 2017($0.2670)($0.20)+$0.0670($0.20)$4.79 million
3/23/2017Q4 2016($0.28)($0.30)($0.02)($0.30)
11/9/2016Q3 2016($0.31)($0.25)+$0.06($0.25)  
8/9/2016Q2($0.32)($0.30)+$0.02($0.30)
5/11/2016Q1($0.28)($0.29)($0.01)($0.29)  
3/29/2016Q4($0.35)($0.26)+$0.09($0.26)  
11/12/2015Q315($0.33)($0.27)+$0.06($0.27)  
8/10/2015Q215($0.42)($0.09)+$0.33($0.09)  
5/7/2015Q1 2015($0.43)($0.44)($0.01)($0.44)
3/18/2015Q414($0.46)($0.87)($0.41)($0.87)
11/12/2014Q314($0.48)($0.44)+$0.04($0.44)












CymaBay Therapeutics Earnings - Frequently Asked Questions

When is CymaBay Therapeutics's earnings date?

CymaBay Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 10th, 2023 based off last year's report dates. Learn more on CBAY's earnings history.

Did CymaBay Therapeutics beat their earnings estimates last quarter?

In the previous quarter, CymaBay Therapeutics (NASDAQ:CBAY) reported ($0.30) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.30). Learn more on analysts' earnings estimate vs. CBAY's actual earnings.

How can I listen to CymaBay Therapeutics's earnings conference call?

The conference call for CymaBay Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read CymaBay Therapeutics's conference call transcript?

The conference call transcript for CymaBay Therapeutics's latest earnings report can be read online. Read Transcript

How much profit does CymaBay Therapeutics generate each year?

CymaBay Therapeutics (NASDAQ:CBAY) has a recorded net income of -$106 million. CBAY has generated -$1.18 earnings per share over the last four quarters.

What is CymaBay Therapeutics's EPS forecast for next year?

CymaBay Therapeutics's earnings are expected to stay at ($1.01) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:CBAY) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -